Vaccine type: Whole Virion Inactivated adjuvanted SARS-CoV-2 vaccine using a Vero Cell manufacturing platform
Commercial name: VLA2001

Developed by: Valneva SE
Location: Saint-Herblain, France
URL: https://www.valneva.com/

VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese encephalitis vaccine, IXIARO®. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018. CpG 1018 adjuvant is supplied by Dynavax Technologies Corporation.

• April 6, 2021: Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
• November 23, 2021: Valneva signed an Advance Purchase Agreement (APA) with the European Commission (EC) to supply up to 60 million doses of its COVID-19 vaccine candidate.
• December 2, 2021: the EMA’s human medicines committee (CHMP) has started a rolling review of VLA2001.
• October 18, 2021: Valneva announced Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001.
• December 8, 2021: Valneva signs advance purchase agreement with Bahrain for 1 million doses

NCT04671017: Immunogenicity and safety of inactivated whole virion Coronavirus vaccine with CpG (VLA2001) in healthy adults aged 18 to 55: a randomised phase 1 /2 clinical trial

NCT04671017 Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults. 
NCT04864561 Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine (COV-COMPARE). 
NCT04956224 Immunogenicity of VLA2101 Compared to VLA2001.